TABLE 1

Summary of Demographics for Pooled Data and for Each Radiopharmaceutical

ParameterAll18F-FDG68Ga-PSMA68Ga-DOTATATEP
Proportion of studies1.00.660.310.03
Extravasation rate (%)1.31.51.100.887
Abnormal time–activity curve (%)9.111.35.400.160
Mean dose (MBq)187.1 (95% CI, 181.8–192.4)204.1 (95% CI, 197.4–210.8)152.9 (95% CI, 150.4–155.5)171.2 (95% CI, 136.5–205.9)<0.001
Male (%)71.059.310050.00.008
Antecubital injection (%)86.184.091.380.00.333
Left side injection (%)70.368.072.890.00.271
Experienced injector*(%)66.964.473.950.00.405
Mean injection score—−209.5 (95% CI, −253.3 to −165.7)———
Mean tHalf25.3 (95% CI, 20.3–30.3)22.9 (95% CI, 19.0–28.6)31.5 (95% CI, 17.6–45.4)13.4 (95% CI, 10.8–16.1)0.206
Mean aUCR101.4 (95% CI, 1.3–1.6)1.6 (95% CI, 1.4–1.7)1.2 (95% CI, 0.9–1.4)1.0 (95% CI, 0.7–1.2)0.007 (PSMA vs. 18F-FDG only)
Mean tc50172.3 (95% CI, 124.3–220.3)195.2 (95% CI, 128.5–261.9)135.6 (95% CI, 71.1–200.0)66.2 (95% CI, 37.1–95.4)0.384
Mean aUCR14.9 (95% CI, 4.1–5.6)6.1 (95% CI, 5.1–7.1)2.6 (95% CI, 1.6–3.6)2.0 (95% CI, 1.3–2.6)<0.001
Mean c1419.1 (95% CI, 382.6–455.7)538.7 (95% CI, 496.7–580.7)193.0 (95% CI, 143.9–242.1)179.8 (95% CI, 128.9–230.8)<0.001
Mean cEndINJ118.1 (95% CI, 113.4–122.9)129.1 (95% CI, 123.6–134.7)98.0 (95% CI, 90.0–106.0)90.1 (95% CI, 65.8–114.4)<0.001 (18F-FDG vs. both 68Ga)
Mean CEndREF123.8 (95% CI, 119.8–127.9)134.3 (95% CI, 129.8–138.8)101.9 (95% CI, 95.3–108.4)122.8 (95% CI, 103.0–142.6)<0.001 (PSMA vs. 18F-FDG and DOTATATE)
Mean CEnd ratio1.02 (95% CI, 0.96–1.08)1.00 (95% CI, 0.93–1.08)1.08 (95% CI, 0.96–1.18)0.79 (95% CI, 0.46–1.12)0.214
Mean ndAvg119.0 (95% CI, 15.1–22.9)25.1 (95% CI, 20.5–29.8)8.3 (95% CI, 1.6–15.1)−1.1 (95% CI, −21.6 to 19.3)<0.001 (18F-FDG vs. both 68Ga)
Mean ndAvgN−0.22 (95% CI, −1.4 to 1.0)0.49 (95% CI, −1.02 to 2.00)−1.1 (95% CI, −3.3 to 1.1)−6.0 (95% CI, −12.7 to 0.6)0.110

  • ↵* Greater than 10 y clinical experience.

  • CI = confidence interval.